Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia.

Erba HP, Becker PS, Shami PJ, Grunwald MR, Flesher DL, Zhu M, Rasmussen E, Henary HA, Anderson AA, Wang ES.

Blood Adv. 2019 Jul 9;3(13):1939-1949. doi: 10.1182/bloodadvances.2019030916.

2.

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.

Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Hall AC, Jacoby M, Lancet J, LeBlanc TW, Mannis G, Marcucci G, Martin MG, Mims A, O'Donnell MR, Olin R, Peker D, Perl A, Pollyea DA, Pratz K, Prebet T, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wieduwilt M, Gregory KM; OCN, Hammond L, Ogba N.

J Natl Compr Canc Netw. 2019 Jun 1;17(6):721-749. doi: 10.6004/jnccn.2019.0028.

PMID:
31200351
3.

Drug-free macromolecular therapeutics induce apoptosis in cells isolated from patients with B cell malignancies with enhanced apoptosis induction by pretreatment with gemcitabine.

Wang J, Li L, Yang J, Clair PM, Glenn MJ, Stephens DM, Radford DC, Kosak KM, Deininger MW, Shami PJ, Kopeček J.

Nanomedicine. 2019 Feb;16:217-225. doi: 10.1016/j.nano.2018.12.011. Epub 2019 Jan 9.

PMID:
30639670
4.

Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia.

Kovacsovics TJ, Mims A, Salama ME, Pantin J, Rao N, Kosak KM, Ahorukomeye P, Glenn MJ, Deininger MWN, Boucher KM, Bavisotto LM, Gutierrez-Sanchez G, Kennedy TP, Marcus SG, Shami PJ.

Blood Adv. 2018 Feb 27;2(4):381-389. doi: 10.1182/bloodadvances.2017013391.

5.

Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.

O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Bhatt V, Bixby D, Blum W, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Gore SD, Hall AC, Kropf P, Lancet J, Maness LJ, Marcucci G, Martin MG, Moore JO, Olin R, Peker D, Pollyea DA, Pratz K, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wang ES, Wieduwilt M, Gregory K, Ogba N.

J Natl Compr Canc Netw. 2017 Jul;15(7):926-957. doi: 10.6004/jnccn.2017.0116.

PMID:
28687581
6.

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, Carraway H, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Horsfall R, Johnson RA, Juckett M, Klimek VM, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Shami PJ, Stein BL, Walker AR, Westervelt P, Zeidan A, Shead DA, Smith C.

J Natl Compr Canc Netw. 2017 Jan;15(1):60-87.

PMID:
28040720
7.

N-(2-Hydroxypropyl)methacrylamide Copolymer-Drug Conjugates for Combination Chemotherapy of Acute Myeloid Leukemia.

Zhang R, Yang J, Zhou Y, Shami PJ, Kopeček J.

Macromol Biosci. 2016 Jan;16(1):121-8. doi: 10.1002/mabi.201500193. Epub 2015 Jul 29.

8.

Phase I trial of low-dose oral Clofarabine in myelodysplastic syndromes patients who have failed frontline therapy.

Rudrapatna VK, Morley K, Boucher KM, Pierson AS, Shull CT, Kushner JP, Shami PJ.

Leuk Res. 2015 Aug;39(8):835-9. doi: 10.1016/j.leukres.2015.05.004. Epub 2015 May 18.

PMID:
26038120
9.

A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab.

Chu TW, Zhang R, Yang J, Chao MP, Shami PJ, Kopeček J.

Theranostics. 2015 Apr 26;5(8):834-46. doi: 10.7150/thno.12040. eCollection 2015.

10.

Myelodysplastic syndromes, version 2.2015.

Greenberg PL, Stone RM, Bejar R, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Klimek V, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Scott B, Shami PJ, Stein BL, Westervelt P, Wheeler B, Shead DA, Smith C; National comprehensive cancer network.

J Natl Compr Canc Netw. 2015 Mar;13(3):261-72.

11.

Drug-free macromolecular therapeutics induce apoptosis of patient chronic lymphocytic leukemia cells.

Chu TW, Kosak KM, Shami PJ, Kopeček J.

Drug Deliv Transl Res. 2014 Dec;4(5-6):389-94. doi: 10.1007/s13346-014-0209-8.

12.

REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.

Stuart RK, Cripe LD, Maris MB, Cooper MA, Stone RM, Dakhil SR, Turturro F, Stock W, Mason J, Shami PJ, Strickland SA, Costa LJ, Borthakur G, Michelson GC, Fox JA, Leavitt RD, Ravandi F.

Br J Haematol. 2015 Mar;168(6):796-805. doi: 10.1111/bjh.13214. Epub 2014 Nov 17.

13.

Effect of a Pluronic(®) P123 formulation on the nitric oxide-generating drug JS-K.

Kaur I, Kosak KM, Terrazas M, Herron JN, Kern SE, Boucher KM, Shami PJ.

Pharm Res. 2015 Apr;32(4):1395-406. doi: 10.1007/s11095-014-1542-9. Epub 2014 Oct 18.

14.

Targeting Glutathione S-transferase M4 in Ewing sarcoma.

Zhuo R, Kosak KM, Sankar S, Wiles ET, Sun Y, Zhang J, Ayello J, Prestwich GD, Shami PJ, Cairo MS, Lessnick SL, Luo W.

Front Pediatr. 2014 Aug 6;2:83. doi: 10.3389/fped.2014.00083. eCollection 2014.

15.

Response monitoring, tolerability, and effectiveness of imatinib treatment for chronic myeloid leukemia in a retrospective research database.

Stenehjem DD, Albright F, Kuo KL, Raimundo K, Bauer H, Shami PJ, Deininger MW, Chen L, Brixner DI.

J Natl Compr Canc Netw. 2014 Aug;12(8):1113-21.

PMID:
25099443
16.

Acute myeloid leukemia, version 2.2013.

O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Lancet J, Maness LJ, Marcucci G, Martin MG, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Wang ES, Gregory KM, Naganuma M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2013 Sep 1;11(9):1047-55.

17.

Cellular distribution studies of the nitric oxide-generating antineoplastic prodrug O(2) -(2,4-dinitrophenyl)1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate formulated in Pluronic P123 micelles.

Kaur I, Terrazas M, Kosak KM, Kern SE, Boucher KM, Shami PJ.

J Pharm Pharmacol. 2013 Sep;65(9):1329-36. doi: 10.1111/jphp.12100. Epub 2013 Jul 10.

18.

Myelodysplastic syndromes: clinical practice guidelines in oncology.

Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, Frankfurt O, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, O'Donnell MR, Shami PJ, Stein BL, Stone RM, Thompson JE, Westervelt P, Wheeler B, Shead DA, Naganuma M.

J Natl Compr Canc Netw. 2013 Jul;11(7):838-74.

19.

Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI.

Weidensteiner C, Reichardt W, Shami PJ, Saavedra JE, Keefer LK, Baumer B, Werres A, Jasinski R, Osterberg N, Weyerbrock A.

Nitric Oxide. 2013 Apr 1;30:17-25. doi: 10.1016/j.niox.2013.01.003. Epub 2013 Jan 28.

20.

Management of extramedullary leukemia as a presentation of acute myeloid leukemia.

Slomowitz SJ, Shami PJ.

J Natl Compr Canc Netw. 2012 Sep;10(9):1165-9.

PMID:
22956813
21.

NCCN Clinical Practice Guidelines Acute myeloid leukemia.

O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E, Borate U, Coutre SE, Damon LE, Goorha S, Lancet J, Maness LJ, Marcucci G, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES, Naganuma M, Gregory KM.

J Natl Compr Canc Netw. 2012 Aug;10(8):984-1021.

PMID:
22878824
22.

Structural modifications modulate stability of glutathione-activated arylated diazeniumdiolate prodrugs.

Nandurdikar RS, Maciag AE, Holland RJ, Cao Z, Shami PJ, Anderson LM, Keefer LK, Saavedra JE.

Bioorg Med Chem. 2012 May 1;20(9):3094-9. doi: 10.1016/j.bmc.2012.02.045. Epub 2012 Mar 9.

23.

How to choose frontline therapy for chronic myelogenous leukemia: so many drugs, not so many patients.

Shami PJ.

J Natl Compr Canc Netw. 2012 Jan;10(1):112-8; quiz 119. Review.

PMID:
22223871
24.

Chronic myelogenous leukemia.

O'Brien S, Abboud CN, Akhtari M, Altman J, Berman E, DeAngelo DJ, Devine S, Fathi AT, Gotlib J, Jagasia M, Moore JO, Pinilla-Ibarz J, Radich JP, Reddy VV, Shah NP, Shami PJ, Smith BD, Snyder DS, Wetzler M, Yunus F; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Jan;10(1):64-110. No abstract available.

PMID:
22223870
25.

Thiol Modification By Pharmacologically Active Agents of the Diazeniumdiolate Class.

Maciag AE, Holland RJ, Saavedra JE, Chakrapani H, Shami PJ, Keefer LK.

For Immunopathol Dis Therap. 2012;3(2):91-95.

26.

Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs.

Maciag AE, Nandurdikar RS, Hong SY, Chakrapani H, Diwan B, Morris NL, Shami PJ, Shiao YH, Anderson LM, Keefer LK, Saavedra JE.

J Med Chem. 2011 Nov 24;54(22):7751-8. doi: 10.1021/jm2004128. Epub 2011 Oct 28.

27.

Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy.

Shami PJ, Deininger M.

Leukemia. 2012 Feb;26(2):214-24. doi: 10.1038/leu.2011.217. Epub 2011 Aug 16. Review.

PMID:
21844872
28.

NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia.

O'Brien S, Berman E, Moore JO, Pinilla-Ibarz J, Radich JP, Shami PJ, Smith BD, Snyder DS, Sundar HM, Talpaz M, Wetzler M.

J Natl Compr Canc Netw. 2011 Feb;9 Suppl 2:S1-25.

29.

Acute myeloid leukemia.

O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Coutre SE, Damon LE, Foran JM, Goorha S, Maness LJ, Marcucci G, Maslak P, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Mar;9(3):280-317. No abstract available.

PMID:
21393440
30.

Treatment of acute lymphoblastic leukemia in adults.

Narayanan S, Shami PJ.

Crit Rev Oncol Hematol. 2012 Jan;81(1):94-102. doi: 10.1016/j.critrevonc.2011.01.014. Epub 2011 Feb 25. Review.

PMID:
21353591
31.

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.

Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Schroeder MA, Shami PJ, Stone RM, Thompson JE, Westervelt P; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Jan;9(1):30-56.

32.

The nitric oxide prodrug JS-K is effective against non-small-cell lung cancer cells in vitro and in vivo: involvement of reactive oxygen species.

Maciag AE, Chakrapani H, Saavedra JE, Morris NL, Holland RJ, Kosak KM, Shami PJ, Anderson LM, Keefer LK.

J Pharmacol Exp Ther. 2011 Feb;336(2):313-20. doi: 10.1124/jpet.110.174904. Epub 2010 Oct 20.

33.

JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo.

Kiziltepe T, Anderson KC, Kutok JL, Jia L, Boucher KM, Saavedra JE, Keefer LK, Shami PJ.

J Pharm Pharmacol. 2010 Jan;62(1):145-51. doi: 10.1211/jpp.62.01.0017.

34.

4'-O-methylglycosylation of curcumin by Beauveria bassiana.

Zeng J, Yang N, Li XM, Shami PJ, Zhan J.

Nat Prod Commun. 2010 Jan;5(1):77-80.

PMID:
20184026
35.

JS-K, a nitric oxide prodrug, has enhanced cytotoxicity in colon cancer cells with knockdown of thioredoxin reductase 1.

Edes K, Cassidy P, Shami PJ, Moos PJ.

PLoS One. 2010 Jan 20;5(1):e8786. doi: 10.1371/journal.pone.0008786.

36.

Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.

Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T, Gabrilove J, Craig M, Douer D, Maris M, Petersdorf S, Shami PJ, Yeager AM, Eckert S, Abichandani R, Faderl S.

J Clin Oncol. 2010 Feb 1;28(4):549-55. doi: 10.1200/JCO.2009.23.3130. Epub 2009 Dec 21.

PMID:
20026805
37.

NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromes.

Greenberg PL, Rigsby CK, Stone RM, Deeg HJ, Gore SD, Millenson MM, Nimer SD, O'Donnell MR, Shami PJ, Kumar R.

J Natl Compr Canc Netw. 2009 Dec 29;7 Suppl 9:S1-16.

PMID:
20064286
38.

NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.

O'Brien S, Berman E, Borghaei H, Deangelo DJ, Devetten MP, Devine S, Erba HP, Gotlib J, Jagasia M, Moore JO, Mughal T, Pinilla-Ibarz J, Radich JP, Shah Md NP, Shami PJ, Smith BD, Snyder DS, Tallman MS, Talpaz M, Wetzler M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2009 Oct;7(9):984-1023. No abstract available.

PMID:
19878641
39.

Synthesis and evaluation of piperazine and homopiperazine analogues of JS-K, an anti-cancer lead compound.

Nandurdikar RS, Maciag AE, Citro ML, Shami PJ, Keefer LK, Saavedra JE, Chakrapani H.

Bioorg Med Chem Lett. 2009 May 15;19(10):2760-2. doi: 10.1016/j.bmcl.2009.03.115. Epub 2009 Mar 28.

40.

Gene expression profiling for nitric oxide prodrug JS-K to kill HL-60 myeloid leukemia cells.

Liu J, Malavya S, Wang X, Saavedra JE, Keefer LK, Tokar E, Qu W, Waalkes MP, Shami PJ.

Genomics. 2009 Jul;94(1):32-8. doi: 10.1016/j.ygeno.2009.03.005. Epub 2009 Apr 5.

41.

JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C).

Shami PJ, Maciag AE, Eddington JK, Udupi V, Kosak KM, Saavedra JE, Keefer LK.

Leuk Res. 2009 Nov;33(11):1525-9. doi: 10.1016/j.leukres.2009.01.002. Epub 2009 Feb 3.

42.

Myelodysplastic syndromes.

Greenberg PL, Attar E, Battiwalla M, Bennett JM, Bloomfield CD, DeCastro CM, Deeg HJ, Erba HP, Foran JM, Garcia-Manero G, Gore SD, Head D, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Saba HI, Shami PJ, Spiers K, Stone RM, Tallman MS, Westervelt P; NCCN Myelodysplastic Syndromes Panel.

J Natl Compr Canc Netw. 2008 Oct;6(9):902-26. No abstract available.

PMID:
18926100
43.

Synthesis and in vitro anti-leukemic activity of structural analogues of JS-K, an anti-cancer lead compound.

Chakrapani H, Goodblatt MM, Udupi V, Malaviya S, Shami PJ, Keefer LK, Saavedra JE.

Bioorg Med Chem Lett. 2008 Feb 1;18(3):950-3. doi: 10.1016/j.bmcl.2007.12.044. Epub 2008 Jan 4.

44.

JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells.

Kiziltepe T, Hideshima T, Ishitsuka K, Ocio EM, Raje N, Catley L, Li CQ, Trudel LJ, Yasui H, Vallet S, Kutok JL, Chauhan D, Mitsiades CS, Saavedra JE, Wogan GN, Keefer LK, Shami PJ, Anderson KC.

Blood. 2007 Jul 15;110(2):709-18. Epub 2007 Mar 23. Erratum in: Blood. 2007 Dec 15;110(13):4187.

45.

Antitumor activity of JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and related O2-aryl diazeniumdiolates in vitro and in vivo.

Shami PJ, Saavedra JE, Bonifant CL, Chu J, Udupi V, Malaviya S, Carr BI, Kar S, Wang M, Jia L, Ji X, Keefer LK.

J Med Chem. 2006 Jul 13;49(14):4356-66.

PMID:
16821795
46.

PABA/NO as an anticancer lead: analogue synthesis, structure revision, solution chemistry, reactivity toward glutathione, and in vitro activity.

Saavedra JE, Srinivasan A, Buzard GS, Davies KM, Waterhouse DJ, Inami K, Wilde TC, Citro ML, Cuellar M, Deschamps JR, Parrish D, Shami PJ, Findlay VJ, Townsend DM, Tew KD, Singh S, Jia L, Ji X, Keefer LK.

J Med Chem. 2006 Feb 9;49(3):1157-64.

47.

JS-K, a nitric oxide prodrug, induces cytochrome c release and caspase activation in HL-60 myeloid leukemia cells.

Udupi V, Yu M, Malaviya S, Saavedra JE, Shami PJ.

Leuk Res. 2006 Oct;30(10):1279-83. Epub 2006 Jan 24.

PMID:
16439016
48.

Pancreatic carcinoma surveillance in patients with familial melanoma.

Parker JF, Florell SR, Alexander A, DiSario JA, Shami PJ, Leachman SA.

Arch Dermatol. 2003 Aug;139(8):1019-25.

PMID:
12925390
49.

Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy.

Elenitoba-Johnson KS, Jenson SD, Abbott RT, Palais RA, Bohling SD, Lin Z, Tripp S, Shami PJ, Wang LY, Coupland RW, Buckstein R, Perez-Ordonez B, Perkins SL, Dube ID, Lim MS.

Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7259-64. Epub 2003 May 19.

50.

JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity.

Shami PJ, Saavedra JE, Wang LY, Bonifant CL, Diwan BA, Singh SV, Gu Y, Fox SD, Buzard GS, Citro ML, Waterhouse DJ, Davies KM, Ji X, Keefer LK.

Mol Cancer Ther. 2003 Apr;2(4):409-17.

Supplemental Content

Loading ...
Support Center